Welcome to our dedicated page for Orthofix Medical SEC filings (Ticker: OFIX), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Our SEC filing database is enhanced with expert analysis from Rhea-AI, providing insights into the potential impact of each filing on Orthofix Medical's stock performance. Each filing includes a concise AI-generated summary, sentiment and impact scores, and end-of-day stock performance data showing the actual market reaction. Navigate easily through different filing types including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, proxy statements (DEF 14A), and Form 4 insider trading disclosures.
Designed for fundamental investors and regulatory compliance professionals, our page simplifies access to critical SEC filings. By combining real-time SEC filing updates, Rhea-AI's analytical insights, and historical stock performance data, we provide comprehensive visibility into Orthofix Medical's regulatory disclosures and financial reporting.
Orthofix Medical Inc. (OFIX) is the issuer in a Form 144 filing by Patrick Fisher, an officer, covering a proposed resale of company common stock under Rule 144. The notice contemplates the sale of 450 shares of Orthofix common stock through Morgan Stanley Smith Barney on NASDAQ.
The 450 shares relate to Restricted Stock Units acquired from the issuer on 08/15/2025. The filing also reports that during the past three months Patrick Fisher sold 1,295 shares of Orthofix common stock on 08/18/2026.
Orthofix Medical Inc. (OFIX) reported that Patrick Fisher, President, Global Limb Recon, sold 1,295 shares of common stock on 2026-08-18 at $10.09 per share. The sale was executed solely to satisfy tax withholding obligations under a pre-approved, mandatory sell-to-cover arrangement and involved no discretion by Fisher. Following this transaction, he holds 51,219 shares directly, including 36,028 restricted stock units and 1,881 shares acquired under Orthofix's Stock Purchase Plan.
Orthofix Medical Inc. (symbol: OFIX) is the issuer of record for a Form 4 filing submitted to the SEC.
Armistice Capital, LLC and Steven Boyd report updated beneficial ownership of Orthofix Medical Inc. common stock in Amendment No. 8 to their Schedule 13G. As of June 30, 2026, they report beneficial ownership of 3,264,000 shares, representing 8.01% of Orthofix’s common stock. They hold shared voting and dispositive power over all 3,264,000 shares and no sole voting or dispositive power. The shares are directly held by Armistice Capital Master Fund Ltd., for which Armistice Capital serves as investment manager under an Investment Management Agreement. The Master Fund has the right to receive dividends and sale proceeds from the reported securities.
Orthofix Medical reported Q2 2026 net sales of $210.9 million, up 3.8% on a reported basis and 4.7% on a pro forma constant-currency basis versus Q2 2025. Growth was driven by double‑digit constant‑currency increases in Global Spine Fixation and Global Limb Reconstruction, 3% growth in Therapeutic Solutions, and stabilizing Biologics.
GAAP gross margin was 71.0%, or 71.7% on an adjusted basis. The company recorded a net loss of $15.8 million, or $0.39 per share, slightly wider than a year ago, while non‑GAAP adjusted EBITDA was $20.1 million, or 9.6% of pro forma net sales, modestly below the prior-year quarter. Cash, cash equivalents and restricted cash were $104.4 million at June 30, 2026, with long‑term debt of $221.6 million; cash declined sequentially mainly due to arbitration award and settlement payments to former executives.
Reflecting Q2 performance and restored Medicare reimbursement for non‑invasive bone growth stimulators, Orthofix raised its 2026 non‑GAAP pro forma guidance to net sales of $845–$855 million and adjusted EBITDA of $95–$98 million, which at the midpoint implies about 5% constant‑currency revenue growth and 80 basis points of adjusted EBITDA margin expansion versus 2025.
Orthofix Medical Inc. reported a regulatory update affecting its non-invasive bone growth stimulators. The FDA reclassified these devices from Class III to Class II on April 16, 2026. After initially changing billing rules from May 18, 2026, CMS later reversed course.
On July 1, 2026, CMS issued revised guidance directing that Medicare claims for devices billed under HCPCS codes E0747, E0748 and E0760 from May 18, 2026 onward be processed and paid as they were before the FDA reclassification. The company currently expects average Medicare reimbursement for these codes to return to pre–May 18, 2026 levels, though it cautions that actual results depend on how the revised rules are implemented and on future claim volumes and payer behavior.
Orthofix Medical Inc. executive Aviva McPherron reported selling 3,670 shares of common stock at $9.38 per share on an open market transaction. According to the footnote, the sale was mandated to satisfy tax withholding for restricted stock unit settlement under a pre-approved sell-to-cover program. McPherron still holds 66,330 shares directly, including 44,748 restricted stock units and 2,147 shares acquired through Orthofix’s Stock Purchase Plan.
Orthofix Medical Inc. director Alan Lee Bazaar received an equity award of 14,965 deferred stock units of common stock. The units were granted at no cash cost and will vest in full on the first anniversary of the grant date, conditioned on continued board service.
After this grant, Bazaar holds 65,489 shares and units in total, including 42,929 previously reported deferred stock units and 700 shares acquired under Orthofix’s Stock Purchase Plan. Each deferred stock unit represents the right to receive one share of common stock, which will settle within 45 days after his service with Orthofix ends.
Orthofix Medical Inc. director Charles R. Kummeth reported receiving an award of 14,965 deferred stock units of common stock as a compensation grant. The units were granted at $0.00 per share, indicating they are not an open-market purchase but an equity award.
The deferred stock units vest in full on the first anniversary of the grant date, subject to his continued service. Each vested unit represents the right to receive one share of Orthofix common stock, which will be delivered within 45 days after his termination of service. Following this award, Kummeth holds 76,305 shares in total, including 42,343 previously reported deferred stock units and 2,103 shares acquired under Orthofix’s Stock Purchase Plan.